Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage

Ralf A. Linker1, Peter Brechlin2,3, Sarah Jesse4, Petra Steinacker4, D. H. Lee1, Abdul R. Asif5, Olaf Jahn3,6, Hayrettin Tumani4, Ralf Gold1, Markus Otto4*

1 Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany, 2 Department of Neurodegeneration and Restorative Research, Center of Neurological Medicine, University of Goettingen, Goettingen, Germany, 3 DFG Research Center for Molecular Physiology of the Brain, Goettingen, Germany, 4 Department of Neurology, University of Ulm, Ulm, Germany, 5 Department of Clinical Chemistry, University of Goettingen, Goettingen, Germany, 6 Max-Planck-Institute for Experimental Medicine, Goettingen, Germany

Abstract

The identification of new biomarkers is of high interest for the prediction of the disease course and also for the identification of pathomechanisms in multiple sclerosis (MS). To specify markers of the chronic disease phase, we performed proteome profiling during the later phase of myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (MOG-EAE, day 35 after immunization) as a model disease mimicking many aspects of secondary progressive MS. In comparison to healthy controls, high resolution 2 dimensional gel electrophoresis revealed a number of regulated proteins, among them glial fibrillary acidic protein (GFAP). Phase specific up-regulation of GFAP in chronic EAE was confirmed by western blotting and immunohistochemistry. Protein levels of GFAP were also increased in the cerebrospinal fluid of MS patients with specificity for the secondary progressive disease phase. In a next step, proteome profiling of an EAE model with enhanced degenerative mechanisms revealed regulation of alpha-internexin, syntaxin binding protein 1, annexin V and glutamate decarboxylase in the ciliary neurotrophic factor (CNTF) knockout mouse. The identification of these proteins implicates an increased apoptosis and enhanced axonal disintegration and correlate well the described pattern of tissue injury in CNTF −/− mice which involve oligodendrocyte (OL) apoptosis and axonal injury. In summary, our findings underscore the value of proteome analyses as screening method for stage specific biomarkers and for the identification of new culprits for tissue damage in chronic autoimmune demyelination.

Introduction

The recent years faced substantial advance in early and at the same time accurate diagnosis of multiple sclerosis (MS, [1,2]). Yet, the need for reliable markers of disease prognosis is still unmet. While magnetic resonance imaging (MRI) has been proven useful in the early disease phases, the present routine MRI protocols are only of limited value for the prediction of long term prognosis of MS [3]. Thus, stage specific prognostic biomarkers are of high interest for accurate patient counseling. Still, evidence on the reliability of some present-day biomarkers is conflicting (for review see [4,5]). While first data pointed at the value of serum anti-myelin antibodies as predictor of clinically definite MS, this could not be reproduced in follow-up studies [6,7]. Some studies identified the intrathecal synthesis of oligoclonal IgM as predictor of an aggressive course of MS [8,9], while it does not predict an early diagnosis [10]. Screening for polymorphisms associated with disease progression led to the identification of variations in the gene of the signaling molecule PD1 as genetic modifier [11] and a genome wide association studies identified the IL2RA and IL7RA as risk factors for MS [12]. For further systematic identification of candidate genes, expression profiling in MS may prove useful [13–15]. In the recent years, a vast number of gene array studies in MS were carried out and mainly allowed insights in therapeutic mechanisms or were employed to determine the response to immunomodulatory treatment (for example [16]). In contrast, only few studies addressed the systematic identification of regulated proteins so far [17]. In fact, protein profiling mainly focused on the screening for autoantibodies in autoimmune diseases [18].

Best candidates for prognosis relevant proteins may be those directly derived from the central nervous system (CNS) as target tissue of the immune reaction. Since the ready availability of these proteins in MS may prove difficult, it seems worthwhile to first investigate their regulation in experimental models. In particular, myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (MOG-EAE) mimics many features of relapsing-progressive or secondary progressive MS [19,20]. Indeed, gene expression profiling revealed differential gene regulation in the CNS as well as the microvascular compartment of EAE diseased mice [21,22]. Recently, the differential expression...
of proteins in the inflamed spinal cord was also described by proteomic analysis using isobaric tags [23] and in correlation to immunohistochemistry [24]. While all these studies showed the technical feasibility of genomic or proteomic analyses in autoimmune demyelination, a candidate marker protein which could be directly transferred from the experimental screening to the clinical situation has not been described so far.

Here we employed proteome profiling of MOG-EAE and the cilary neurotrophic factor knockout mouse (CNTF−/− mouse) as model with enhanced tissue injury including axonal degeneration and oligodendrocyte (OL) apoptosis to screen for disease regulated proteins which could serve as candidate biomarkers in MS patients.

Materials and Methods

Animals

C57BL/6 mice were purchased from Harlan (Borchen, Germany) and kept at the animal care facilities of the Institute for MS Research, University of Göttingen, Germany. CNTF−/− mice were backcrossed to the C57BL/6 background for more than 14 generations and bred at the in-house animal care facilities. These mice were characterized in detail in previous studies and display an increased OL apoptosis and enhanced axonal degeneration over the later phases of MOG-EAE [25,26]. All animal experiments were performed in accordance with the Lower Saxony State regulations for animal welfare.

Induction and clinical evaluation of active MOG-EAE

For active induction of EAE, mice received a s.c. injection at flanks and tail base of 200 μg MOG 35–55 peptide (Charité, Berlin, Germany) in PBS emulsified in an equal volume of CFA containing Mycobacterium tuberculosis H37RA (Difco, Detroit MI, USA) at a final concentration of 1 mg/ml. Two injections of pertussis toxpin (List Biochemicals, Campbell, CA, USA, 400 ng per mouse i.p.) were given at the time of immunization and 48 hours later. Animals were weighed and scored for clinical signs of disease on a daily basis using a clinical score as described previously [25].

Tissue processing

On day 35 or 37 after immunization (p.i.), mice were anesthetized with Ketanest (Intresa, Freiburg, Germany) and Rompun (Bayer, Leverkusen, Germany), transcardially perfused with saline and spinal cords were carefully removed. For postfixation in the same fixative for two hours. Subsequently, axial paraffin sections (3 μm) or, after resin embedding, semi-thin sections (0.5 μm) were obtained.

Immunohistochemistry and histopathology

Histopathological evaluation included anti-GFAP immunohistochemistry (rat anti-GFAP, dilution 1:1000, DAKO) and toluidine blue staining of semi-thin sections. For GFAP staining, the primary antibody was incubated overnight at 4°C. After washing, sections were incubated with the appropriate secondary antibody (Invitrogen Hamburg, Germany) at a dilution of 1:100) and developed using diaminobenzidine (DAB) as chromogenic substrate. Specificity of staining was confirmed by omitting the primary antibody. Sections were mounted with Entellan (Sigma) and analyzed by light microscopy (Olympus, Hamburg, Germany).

Two-dimensional difference gel electrophoresis (2D DIGE)

First-dimension isoelectric focusing was performed with immobilized pH 3 to 10 nonlinear gradient gels (24-cm Immobiline dry strips pH 3–10 NL; GE Healthcare). IPG strips were rehydrated for 24 h in 7 M urea—2 M thiourea—4% CHAPS—1% dithiothreitol (DTT)—0.4% IPG buffer pH 3–10 NL—0.002% bromophenol blue. Whole spinal cord samples were dissolved in 3 volumes of ice-cold acetone and precipitated overnight at −20°C. Proteins were pelleted, air dried for 1 h, and lysed in 7 M urea—2 M thiourea—4% CHAPS-30 mM Tris-HCl (pH 8.1) by rocking for 1 h at ambient temperature for subsequent labeling. Insoluble material was removed by centrifugation. The proteins were labeled as specified by the manufacturer with fluorescent dyes specifically developed for the two-dimensional 2D difference gel electrophoresis system (2D-DIGE) (CyDyes Cy2, Cy3, and Cy5 [GE Healthcare]). For the mixed internal standard, aliquots of each individual sample included in the experiment were pooled and labeled with Cy2 in the same dye-to-sample ratio. After 30 min incubation at 8°C in the dark, the labeling reaction was abrogated by adding 20 nmol lysine and incubating for further 10 min. The labeled samples were combined and diluted 1.33 fold by a stock solution containing 7 M urea, 2 M thiourea, 4% CHAPS, 4% IPG buffer 4–7, 4% DTT w/v for subsequent IEF. Labeled samples were cup-loaded near the anodic end, and isoelectric focusing was carried out for a total of 56000 Vh (1 h 150 V, ramp for 3 h to 300 V, ramp for 6 h to 1000 V, ramp for 5 h to 8000 V, hold at 8000 V for 4:40 h). After focusing, the strips were equilibrated for two 25-min intervals in 6 M urea—125 mM Tris-HCl (pH 7.85)—3% SDS-20 (vol/vol) glycerol; 1% DTT was added for the first equilibration step, and 4.2% iodoacetamide (IAA) was added for the second equilibration step. Second dimension SDS-PAGE was performed with homogeneous 11% polyacrylamide gels (254 by 200 mm) by the method of Tastet et al. [27] with 150 g Tris/0.6 M HCl as gel buffer and 4% CHAPS—30 mM Tris/HCl (pH 8.1) as running buffer. Taurine instead of glycine as buffering ion in the running buffer at 4 W/gel overnight at 25°C. The fluorescent signals of the three differently CyDye-labeled protein samples were imaged using a laser scanner recording band pass filtered emission wavelengths of 520 nm (Cy2); 580 nm (Cy3) and 670 nm (Cy5) respectively (Typhoon 9400 GE Healthcare). For comparison of wild type mice with or without EAE a set of 2 gels were run in a dye swap manner. For the comparison of CNTF knockout mice with wild-type controls, a set of 6 gels were run, with a total of 6 individual samples per group. The gels were analyzed with the different software modules of the DeCyder differential analysis software (GE Healthcare). Proteins were post-stained with colloidal Coomassie. Spots of interest were excised manually as described previously [28] and subjected to mass spectrometric protein identification.

Protein identification

Proteins were identified by two approaches as described recently [29,30]. Briefly, an automated platform was used to digest the proteins in-gel with trypsin and to prepare the proteolytic peptides for MALDI-TOF-MS. For each sample, a peptide mass fingerprint (PMF) spectrum and fragment ion spectra of up to four selected precursor ions were acquired within the same automated analysis loop using an Ultraflex I mass spectrometer (Bruker Daltonics). Data base searches were performed with the Mascot Software 2.0 (Matrix Science) licensed in-house. Only proteins represented by at least one peptide sequence above significance threshold in combination with the presence of at least
four peptide masses assigned in the PMF were considered as identified (for detailed reference see [31,32]).

Protein Sequence Analysis by LC-MS/MS
To confirm the data obtained from mass fingerprint analysis, some samples were subjected to peptide sequence analysis. The peptide sequencing analysis was performed as described elsewhere [29,33]. Briefly, extracted peptides were dissolved in 0.1% formic acid (FA) and one microliter of sample was introduced using a CapLC autosampler (Waters, Manchester, UK) onto a µ-precolumn Cartridge (C18 pepMap, 300 µm × 5 mm; 5 µm particle size; LC Packings Idstein, Germany) and further separated through a C18 pepMap100 nano Series (75 µm × 15 cm; 3 µm particle size) analytical column (LC Packings Idstein, Germany). The mobile phase consisted of solution A (5% ACN in 0.1% FA) and solution B (95% ACN in 0.1% FA). The total sample running time was set to 60 min. Peptide sequencing was performed on a Q-TOF Ultima Global (Waters) mass spectrometer equipped with a nanoflow ESI Z-spray source in the positive ion mode. Multiple charged peptide parent ions were automatically marked and selected in the quadrupole and fragmented in the hexapole collision cell, and their fragment patterns were analyzed by time-of-flight. Data were acquired using MassLynx (v 4.0) software (Waters) on a Windows NT PC, and were further processed on a Protein-Lynx-Global-Server (PLGS) v. 2.1. (Waters, Manchester, UK). The raw data files were deconvoluted and deisotoped using the Max Ent lite algorithm (Waters). A PLGS module was used to generate Mascot-searchable *.pkl files. The *.pkl processed data were searched against a NCBI database via a Mascot search engine using a peptide mass and MS/MS tolerance of 0.5 Da. The search criteria were set with one missed cleavage by trypsin allowed and protein modifications set to methionine oxidation and carbamidomethylcysteine when appropriate.

GFAP Western Blotting
Separation of proteins (homogenates 40 µg/lane), blotting, detection, and quantification of the signals were performed as described [34]. Blots were incubated with rabbit anti-GFAP antibody (DAKO, 1:7500 in 3% MMP/TBST) followed by incubation with a biotinylated anti-rabbit antibody (Vector, 1:10000). The signals were standardized relative to the amount of GFAP in wild-type spinal cord. A representative experiment of two independent analyses is shown (n = 3 for each genotype).

Patients
All analyses were approved by the local ethics committee of the University Ulm. Patients were admitted to the Department of Neurology, University Ulm in 2007. CSF-samples of 22 patients were collected within the scope of the routine work-up and were stored at −80°C until the carrying out of the laboratory experiments. The MS patient group consists of 14 adult patients (age between 19 and 53) who were diagnosed with MS according to the McDonald criteria. Additionally, all patients were classified according to the EDSS score and underwent magnetic resonance imaging (MRI) of the neurocranium and spine. All investigated CSF-samples of MS patients showed oligoclonal bands. At the time of the lumbar puncture, the relapsing remitting MS patients did not receive any disease modifying treatment. In contrast, two patients suffering from secondary-chronic progressive MS received interferon-β therapy. In the control group, eight adult patients (age range between 18 and 44 years) underwent lumbar puncture as a part of the neurologic differential diagnosis. None of these patients presented a chronic inflammatory neurologic disease. The CSF evaluations of these patients were assessed as normal findings. On the occasion, no oligoclonal bands were detected. Both, the cell count and the protein levels were in normal ranges.

Measurement of the GFAP concentrations in CSF samples
Determination of GFAP concentration in the individual samples was performed according to the manufacturer protocol using an enzyme-linked immunoabsorbent assay (ELISA; BioVendor). The analytical limit of detection was 0.033 ng/ml. The sensitivity of the used assay takes the dilution of the samples into consideration and is calculated according to the formula: Assay sensitivity = Analytical limit of detection x sample dilution = 0.033 ng/ml x 3 = 0.1 ng/ml.

Statistical Analysis
The comparison of the GFAP concentrations between the different subgroups was based on nonparametric rank tests (for two groups, Wilcoxon Mann-Whitney-U-test; for more than two groups, the Friedman 2-way ANOVA by ranks). Differences were considered significant at *p<0.05, and ** p<0.01.

Results
Proteome profiling in the chronic phase of murine MOG-EAE
To identify markers of disease progression in chronic progressive autoimmune demyelination, we investigated the regulation of proteins by proteome profiling of the early chronic phase (day 35 p.i.) of MOG-EAE in the C57BL/6 mouse as a model disease. 2DIEF of spinal cord tissue revealed a number of regulated proteins, among them the astrocyte marker glial fibrillary acidic protein (GFAP, see Fig. 1), but also transferrin precursor, calreticulin precursor and protein disulfide isomerase precursor (Table 1).

Confirmation of GFAP up-regulation in the spinal cord of chronic MOG-EAE
We aimed to confirm GFAP as a regulated marker protein in murine MOG-EAE. To that end, protein levels of GFAP were investigated by Western Blot (Fig. 2) over the course of the disease at an early chronic (day 35 p.i.) and late chronic time point of MOG-EAE (day 60 p.i.). Quantification of protein levels revealed a significant, up to 2 fold increase of GFAP protein levels in the later disease phases (Fig. 2B). These data were correlated with GFAP immunohistochemistry which revealed thin GFAP positive astrocytes without gliosis in naive control mice while over the course of MOG-EAE, astrocytes displayed strongly GFAP positive stellar shaped cell bodies accompanied by a diffuse GFAP staining indicating fibrillary gliosis (Fig. 2C).

Regulation of GFAP in the CSF of MS patients
To prove the relevance of GFAP as a regulated protein in human autoimmune demyelination, we investigated this candidate marker in the CSF of MS patients. There was a significant increase of GFAP protein in patients suffering from secondary progressive MS, whereas patient with a relapsing remitting disease course displayed levels similar to healthy controls (see Table 2 for baseline characteristics of patients and Fig. 3A,B for results). The GFAP levels for secondary chronic progressive MS patients were between 1.7 ng/ml to 2.4 ng/ml (median 2.05 ng/ml) and in the relapsing remitting group between 0.567 ng/ml to 1.273 pg/ml (median...
In the control group, patients displayed levels between 0.507 ng/ml to 1.595 ng/ml (median: 0.961 ng/ml). Proteome profiling in a disease model with enhanced tissue damage

Finally, we were interested to investigate marker proteins not only correlating with the disease stage, but also patterns of tissue damage. Thus, we investigated the regulation of proteins after induction of MOG-EAE in the model of the CNTF \(^2\)/\(^2\) mouse, a well characterized paradigm with enhanced OL apoptosis and axon damage on days 28 and 56 p.i. after immunization [25].

Proteome profiling of the early chronic phase of MOG-EAE in CNTF \(^2\)/\(^2\) versus wild-type mice was performed on day 37 p.i.

At this time, CNTF \(^2\)/\(^2\) mice displayed a more pronounced motor impairment as compared to matched controls (mean clinical score \(\pm\) SEM: 6.1\(\pm\)0.6 in CNTF \(^2\)/\(^-\) mice vs. 4.6\(\pm\)0.7 in wild-type mice, \(p = 0.02\)). Proteomic analyses revealed a number of significantly regulated proteins (Table 3) as proven by analysing groups of individual mice. While this approach did not reveal the regulation of the stage-specific marker GFAP as associated with enhanced tissue damage, the analysis disclosed an increase in the axonal structure proteins alpha-internexin as part of the neurofilament apparatus and also syntaxin binding protein 1 in CNTF \(^2\)/\(^-\) mice (see Fig. 4 for gel and Fig. 5 for quantitative analysis). Moreover, CNTF \(^2\)/\(^-\) mice displayed an increase in annexin V as apoptosis marker, but a decrease in glutamate decarboxylase which is involved in glutamate metabolism and also altered in demyelinated lesions [35]. Finally, we identified an increase in RAP1 (GTP-GDP dissociation stimulator 1) and a decrease of enolase-phosphatase 1 in CNTF \(^2\)/\(^-\) mice (see table 3) as proteins of the cellular metabolism with a so far miscellaneous function in EAE. These changes were not found in first analyses comparing naive CNTF \(^2\)/\(^-\) and wild-type mice.

In summary, the regulated proteins point at an increased apoptosis and glutamate mediated excitotoxicity along with changes in the axonal neurofilament apparatus in EAE diseased CNTF \(^2\)/\(^-\) mice. These observations correlate well with the destructive pathology and also OL apoptosis in EAE lesions of CNTF deficient mice on day 35 p.i. (Fig. 6) which were already described on days 28 and 56 p.i. in earlier studies [25].

**Discussion**

Here we performed proteome profiling of murine MOG-EAE as a model of secondary progressive MS.

First, our data reveal an up-regulation of GFAP in the spinal cord in the chronic disease phase of MOG-EAE. These findings could be transferred from the experimental model to the clinical setting with an increase of GFAP also in the CSF of secondary progressive MS patients. An increase of GFAP expression during autoimmune demyelination was already shown in different models of EAE [36–38] with acute as well as relapsing remitting disease courses. Our data extend these previous findings also to the chronic phase of MOG-EAE. The up-regulation of GFAP in the later phase of the disease implies a role of astroglia during chronicity of autoimmune demyelination. In contrast, some previous studies also point towards a role of glial cells in the regulation of the target tissue response to an inflammatory insult [39]. Here, studies in the model of GFAP knockout mice are somewhat hampered by a complex phenotype with impaired white matter architecture [40].

Moreover, previous data indicate that assessment of GFAP in the CSF of MS patients with a newly developed ELISA may be
Figure 2. Up-regulation of GFAP over the course of MOG-EAE. (A) Western-Blot analysis of spinal cord protein preparation at the early chronic (day 35 p.i.) and late chronic phase of the disease (day 60 p.i.). Each lane represents the GFAP expression of one single mouse, β-actin serves as a loading control. (B) Quantification of optical densities of the GFAP labeling as shown in figure 2A. There was a clear increase in GFAP expression over the course of MOG-EAE (p<0.05 on day 60 p.i.). (C) Immunohistochemistry for GFAP in naïve C57BL/6 mice without EAE (left) and on day 35 p.i. (middle) and 60 p.i. (right). Representative images from spinal cord cross sections are shown, arrows indicate GFAP positive astrocytes which appear elongated in naïve mice and swollen in the chronic phases of MOG-EAE. Bar represents 20 µm.

doi:10.1371/journal.pone.0007624.g002

Table 2.

| Disease Course                      | Number | Age (range) | Gender | EDSS-Score | GFAP (ng/ml; range) |
|-------------------------------------|--------|-------------|--------|------------|---------------------|
| Secondary-chronic progressive MS    | n = 4  | 25–55       | 3 F, 1 M | 5.0–8.5    | 2.05 (1.7–2.4)      |
| Relapsing-remitting MS              | n = 10 | 19–55       | 6 F, 4 M | 2.0–3.5    | 0.815 (0.587–1.275) |
| Non neurological disease            | n = 8  | 18–44       | 4 F, 4 M | n.a.       | 0.961 (0.507–1.595) |

doi:10.1371/journal.pone.0007624.t002
feasible [41]. Indeed, an increase of GFAP was also found in the CSF of MS patients, in particular in secondary progressive MS patients which is well in line with previous observations [37,38] and adds GFAP to other markers like neurofilament or nitric oxide metabolites that were also shown to correlate with disability or disease progression [42,43].

The similar findings on the regulation of GFAP in spinal cord tissue of MOG-EAE and the CSF from secondary progressive MS patients [41] add GFAP to other markers like neurofilament or nitric oxide metabolites that were also shown to correlate with disability or disease progression [42,43].

**Table 3.**

| Spot No. | Protein name                              | Swiss-Prot accession | MW [kDa] | pI  | PMF coverage [%] | PMF scorea | Peptide sequenced                                                                 | MS/MS ion scoreb |
|----------|------------------------------------------|----------------------|----------|-----|-----------------|------------|----------------------------------------------------------------------------------|-------------------|
| I        | Annexin A5                               | P48036               | 35.8     | 4.8 | 23              | 67         | GTVTDFPGFDGR                                                                     | 27                |
|          |                                          |                      |          |     |                 |            | GLGTDDESLNILNTSR                                                                  | 25                |
|          |                                          |                      |          |     |                 |            | FITIFGTR                                                                         | 6                 |
| II       | RAP1, GTP-GDP dissociation stimulator 1   | NCBI:gi|148680137c | 61.1   | 5.4 | 59              | 177        | DLASAQLVOILHR                                                                    | 73                |
|          |                                          |                      |          |     |                 |            | HVEDGNTVQHAAALSR                                                                  | 58                |
| III      | Alpha-internexin                         | P46660               | 55.9     | 5.2 | 50              | 242        | HSAEAVYQDSQLESLDR                                                                  | 139               |
|          |                                          |                      |          |     |                 |            | FSGGLSLGSLNLPNPSYLLPR                                                            | 99                |
| IV       | Syntaxin-binding protein 1               | O08599               | 67.9     | 6.5 | 26              | 82         | DNALLAQIQDK                                                                     | 14                |
|          |                                          |                      |          |     |                 |            | LAEQIATLCATLK                                                                    | 14                |
| VI       | Enolase-phosphatase E1                   | Q88GB7               | 28.7     | 4.8 | 21              | 32         | AEFFADVPAVR                                                                     | 44                |
|          |                                          |                      |          |     |                 |            | LLFGHSTLEGILIDGHDFTK                                                              | 6                 |
| V        | Glutamate dehydrogenase 1, mitochondrial precursor | P26443           | 61.6     | 8.1 | 48              | 162        | HGGAGPVPATAIFQDR                                                                  | 54                |
|          |                                          |                      |          |     |                 |            | IYKPCNHVLSLFSFIR                                                                   | 50                |

*Mascot protein score obtained for the peptide mass fingerprint (PMF). The significance threshold was 54.

*Mascot MS/MS ion scores obtained for the individual peptides sequenced. The significance threshold for identity was 22–28 depending on how many peptides fell within the mass tolerance window about the precursor mass. Only the top ranking peptides matching a query for the first time (“bold red hits”) are reported.

*Data were searched against the NCBI data base as the search against the Swiss-Prot database did not reveal any identification.

doi:10.1371/journal.pone.0007624.t003
patients speak for a good correlation of changes in protein expression in the CNS from the animal model and the CSF compartment in MS patients. Moreover, these data also serve as a proof of principle revealing that proteomics can be a valuable tool for translational medicine. Proteome analysis of murine EAE models may allow the identification of candidate biomarkers which can then be transferred to the respective MS stages in clinical practice. Indeed, CNS derived proteins may not only serve as bulk markers of the disease [44], but could also show stage specificity thus helping to predict disease prognosis.

Second, proteome analysis of MOG-EAE in CNTF −/− mice reveals a regulation of proteins involved in apoptosis (annexin V) and also regulation of excitotoxicity (glutamate decarboxylase). Moreover, CNTF −/− mice displayed an increase in axonal structure proteins like alpha-internexin indicating an enhanced axonal disintegration. These findings correlate well with the previously described histopathological pattern in CNTF −/− mice which includes an increased OL apoptosis and also an enhanced axonal injury. In the light of the decreased expression of glutamate decarboxylase in CNTF −/− mice and the role of glutamate excitotoxicity as a mechanism for axonal damage and OL death in autoimmune demyelination [45], it is tempting to speculate that a decreased glutamate metabolism may lead to enhanced excitotoxicity which then precipitates the pronounced tissue damage in this model.

Other candidate markers which are possibly linked to pathomechanisms of disease and were identified in specimen of MS patients include hypoxia associated factors [46] for ischemic

Figure 4. Proteome analysis of CNTF knockout mice. 2D-DIGE gel of spinal cord proteins from CNTF knock-out mice with EAE, labeled with Cy3 (shown in green) versus wild type mice with EAE labeled with Cy5 (shown in red). Selected proteins identified by Mass Spectrometry are indicated with roman indices (see Fig. 5). Proteins were separated on 24 cm IPG Strip pH 3–10 non-linear.

doi:10.1371/journal.pone.0007624.g004

Figure 5. Statistical evaluation of regulated proteins in CNTF −/− mice. 2D DIGE analysis of the average spot volume increase ratio of proteins shown in Fig. 4. Using the DeCyder’s Biological Variation Analysis module, a paired Student’s t-test yielded a p-value within the 99th percentile confidence level. Mean value crosses are connected; IS = Internal Standard.

doi:10.1371/journal.pone.0007624.g005
In summary, our findings underscore the value of proteome profiling as screening technique for biomarkers determining the disease stage, but also for the identification of prevailing pathomechanisms in autoimmune demyelination. In particular, stage specific EAE models [19] may indicate which molecule bears the highest level of success as biomarker for disease progression not only for EAE itself, but possibly also for MS. While proteomics may help to identify new biomarkers, this technique could also be beneficial to understand pathophysiological changes or to predict treatment responses in chronic inflammatory diseases of the CNS as recently shown for DNA vaccination [18].

Acknowledgments

The skilful technical assistance of Silvia Seubert and Alexandra Bohl is gratefully acknowledged. We thank Dr Evanthia Mergia, Institute of Pharmacology, Ruhr-University Bochum, Germany for technical help with Western Blot analysis and Prof. M. Sendtner, Neurobiology, University Würzburg for continuous support and helpful discussion.

Author Contributions

Conceived and designed the experiments: RAL RG MO. Performed the experiments: RAL PB SJ ARA OJ. Analyzed the data: RAL PS DHL ARA OJ MO. Contributed reagents/materials/analysis tools: HT RG MO. Wrote the paper: RAL RG MO.

References

1. Brex PA, Miszkiel KA, O’Riordan JL, Plant GT, Moseley IF, et al. (2001) Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 70: 390–393.
2. Tiitinen M, Rovira A, Rau J, Nos C, Grive E, et al. (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67: 967–972.
3. Brex PA, Ciccarelli O, O’Riordan JH, Sailer M, Thompson AJ, et al. (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346: 158–164.
4. Bielekova B, Martin R (2004) Development of biomarkers in multiple sclerosis. Curr Med Chem 11: 1956–1965.
5. Kuhle J, Lindberg RL, Regeniter A, Mehling M, Hoffmann F, et al. (2007) Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 254: 169–168.
6. Rauer S, Euler B, Reindl M, Berger T (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77: 719–724.
7. Villar LM, Mañour J, Gonzalez-Porque P, Plaza J, Sadaba MC, et al. (2003) Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53: 222–226.
8. Villar LM, Sadaba MC, Roldan E, Mañour J, Gonzalez-Porque P, et al. (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115: 187–194.
9. Schneider R, Euler B, Rauer S (2007) Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol 14: 907–911.
10. Kroner A, Mehling M, Henner B, Rieckmann P, Toyka KV, et al. (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58: 50–57.
11. Haller DA, Compton A, Sawyer S, Lander ES, Daly MJ, et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851–862.
12. Comabella M, Martin R (2007) Genomics in multiple sclerosis—current state and future directions. J Neuroimmunol 187: 1–8.
13. Fossey SC, Vaessen-Jones CL, Olsen NJ, Sireau S, Garrison G, et al. (2007) Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 9: 197–204.
14. Ibrahim SM, Gold R (2005) Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 18: 231–235.
15. Sturzebecher S, Wandinger KP, Rosenwald A, Sathiyamoorthy M, Tsou A, et al. (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126: 1419–1429.
16. Baloue I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, et al. (2006) Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol 24: 391–418.
17. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, et al. (2003) Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21: 1033–1039.
18. Gold R, Lannington C, Lastmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953–1971.
19. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern of axonal injury in marine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 30: 162–173.
21. Ali C, Duvefelt K, Franzen B, Yang Y, Engvall Arhult B (2005) Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57Bi/6 and SJL mice. Brain Pathol 15: 1–16.

22. Ibrahim SM, Mix E, Botcher T, Kovaczn D, Gold R, et al. (2001) Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 124: 1927–1938.

23. Liu T, Donahue KC, Hu J, Kurnell MP, Grant JE, et al. (2007) Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J Proteome Res 6: 2563–2573.

24. Duzhak T, Emerson MR, Chakrabarty A, Alterman MA, Levine SM (2003) Analysis of protein induction in the CNS of SJL mice with experimental allergic encephalomyelitis by proteomic screening and immunohistochemistry. Cell Mol Biol (Noisy-le-grand) 49: 723–732.

25. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, et al. (2002) CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8: 620–624.

26. Masu Y, Wolf E, Holmman B, Sendtner M, Brem G, et al. (1993) Disruption of the CNTF gene results in motor neuron degeneration. Nature 365: 27–32.

27. Tastet C, Lescuyer P, Diemer H, Luche S, Van DA, et al. (2006) A versatile electrophoresis system for the analysis of high- and low-molecular-weight proteins. Electrophoresis 24: 1787–1794.

28. Steinacker P, Schwan R, Reim K, Brechlin P, Jahn O, et al. (2003) Unchanged survival rates of 14.3-3-gamma knockout mice after inoculation with pathological prion protein. Mol Cell Biol 23: 1339–1346.

29. Asif AR, Oellerich M, Amstrong VW, Riemenschneider B, Monod M, et al. (2008) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17: 607–615.

30. Liedtke W, Edelmann W, Chiu FC, Koechlin D, Raine CS (1998) Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am J Pathol 152: 251–259.

31. Jahn O, Hesse D, Reinelt M, Kratzin HD (2006) Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal Bioanal Chem 386: 92–103.

32. Liedtke W, Edelmann W, Bier PL, Chiu FC, Cowan NJ, et al. (1996) GFAP is a new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis. Neurology 50: 169–180.

33. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

34. Mergia E, Russwurm M, Zoidl G, Koedling D (2003) Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal 15: 189–195.

35. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169–180.

36. Kothavale A, Di GD, Somera FP, Smith ME (1995) GFAP mRNA fluctuates in synchrony with chronic relapsing EAE symptoms in SJL/J mice. Glia 14: 216–224.

37. Prosperi N, Sandstrom P, Svenningsen A, Rosengren I, Stigbrand T, et al. (2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63: 1586–1590.

38. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Identification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

39. Liedtke W, Edelmann W, Chiu FC, Koechlin D, Raine CS (1998) Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am J Pathol 152: 251–259.

40. Liedtke W, Edelmann W, Bier PL, Chiu FC, Cowan NJ, et al. (1996) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17: 607–615.

41. Norgren N, Svenningsson A, Rosengren I, Stigbrand T, et al. (2004) CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63: 1439–1445.

42. Giovannoni G (2006) Multiple sclerosis cerebrospinal fluid biomarkers. J Immunol Methods 287: 169–177.

43. Rejdak K, Eikelenboom MJ, Gveric D, Keir G, Chapman M, et al. (2002) CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63: 1439–1445.

44. Liedtke W, Edelmann W, Chiu FC, Cowan NJ, et al. (1996) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17: 607–615.

45. Liedtke W, Edelmann W, Bier PL, Chiu FC, Cowan NJ, et al. (1996) GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17: 607–615.

46. Liedtke W, Edelmann W, Bier PL, Chiu FC, Cowan NJ, et al. (1996) GFAP is a new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis. Neurology 50: 169–180.

47. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

48. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

49. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

50. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

51. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

52. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

53. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.

54. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, et al. (2003) Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45–48.